Journal of International Medical
The online version of this article can be found at:
2012 40: 1966Journal of International Medical Research
Z-W Xie, Y-N Zhang, S Wan, W-Z Xu and J Chen
Women with Leiomyoma
Levonorgestrel-Releasing Intrauterine Device is an Efficacious Contraceptive for
can be found at:
Journal of International Medical Research
Additional services and information for
What is This?
- Oct 1, 2012 Version of Record >>
by guest on October 11, 2013 by guest on October 11, 2013 by guest on October 11, 2013 by guest on October 11, 2013 by guest on October 11, 2013 by guest on October 11, 2013 by guest on October 11, 2013 by guest on October 11, 2013imr.sagepub.comimr.sagepub.com imr.sagepub.com imr.sagepub.comimr.sagepub.comimr.sagepub.com imr.sagepub.comimr.sagepub.com Downloaded from Downloaded from Downloaded from Downloaded from Downloaded from Downloaded from Downloaded from Downloaded from
Therapeutic use of levonorgestrel-releasing
menorrhagia: a pilot study. Contraception 2002;
65: 325 – 328.
5 Grigorieva V, Chen-Mok M, Tarasova M, et al:
Use of a levonorgestrel-releasing intrauterine
system to treat bleeding related to uterine
leiomyomas. Fertil Steril 2003; 79: 1194 – 1198.
6 Stewart A, Cummins C, Gold L, et al: The
effectiveness of the levonorgestrel-releasing
intrauterine system in menorrhagia: a
systematic review. BJOG 2001; 108: 74 – 86.
7 Zapata LB, Whiteman MK, Tepper NK, et al:
Intrauterine device use among women with
uterine fibroids: a
Contraception 2010; 82: 41 – 55.
8 Ikomi A, Mansell E, Spence-Jones C, et al:
Treatment of menorrhagia
levonorgestrel intrauterine system: can we
learn from our failures? J Obstet Gynaecol 2000;
20: 630 – 631.
9 Maruo T, Matsuo H, Samoto T, et al: Effects of
progesterone on uterine leiomyoma growth
and apoptosis. Steroids 2000; 65: 585 – 592.
10 Higham JM, O’Brien PM, Shaw RW: Assessment
of menstrual blood loss using a pictorial chart.
Br J Obstet Gynaecol 1990; 97: 734 – 739.
11 Soysal S, Soysal ME: The efficacy of
levonorgestrel-releasing intrauterine device in
selected cases of myoma-related menorrhagia:
a prospective controlled trial. Gynecol Obstet
Invest 2005; 59: 29 – 35.
12 Gunes M, Ozdegirmenci O, Kayikcioglu F, et al:
The effect of levonorgestrel intrauterine system
on uterine myomas: a 1-year follow-up study. J
Minim Invasive Gynecol 2008; 15: 735 – 738.
13 Magalhães J, Aldrighi JM, de Lima GR: Uterine
volume and menstrual patterns in users of the
levonorgestrel-releasing intrauterine system
with idiopathic menorrhagia or menorrhagia
due to leiomyomas. Contraception 2007; 75: 193
14 Murat Naki M, Tekcan C, Ozcan N, et al:
Levonorgestrel-releasing intrauterine device
insertion ameliorates leiomyoma-dependent
menorrhagia among women of reproductive
age without a significant regression in the
uterine and leiomyoma volumes. Fertil Steril
2010; 94: 371 – 374.
15 Critchley HO, Wang H, Jones RL, et al:
Morphological and functional features of
endometrial decidualization following long-
term intrauterine levonorgestrel delivery. Hum
Reprod 1998; 13: 1218 – 1224.
in women with
16 Wildemeersch D, Schacht E: The effect on
menstrual blood loss in women with uterine
fibroids of a novel “frameless” intrauterine
levonorgestrel-releasing drug delivery system: a
pilot study. Eur J Obstet Gynecol Reprod Biol 2002;
102: 74 – 79.
17 Sayed GH, Zakherah MS, El-Nashar SA, et al: A
randomized clinical trial of a levonorgestrel-
releasing intrauterine system and a low-dose
combined oral contraceptive for fibroid-related
menorrhagia. Int J Gynaecol Obstet 2011; 112:
126 – 130.
18 Jindabanjerd K, Taneepanichskul S: The use of
levonorgestrel-IUD in the treatment of uterine
myoma in Thai women. J Med Assoc Thai 2006;
89(suppl 4): S147 – S151.
19 Rein MS: Advances in uterine leiomyoma
research: the progesterone hypothesis. Environ
Health Perspect 2000; 108(suppl 5): 791 – 793.
20 Pavlovich SV, Volkov
Proliferative activity and level of steroid
hormone receptors in the myometrium and
myoma nodes in different phases of menstrual
cycle. Bull Exp Biol Med 2003; 136: 396 – 398.
21 Cepický P, Cibula D, Dvorák V, et al:
Recommendations for the levonorgestrel
intrauterine system (LNG-IUS). 2006. Ceska
Gynekol 2007; 72: 149 – 150 [in Czech].
22 Mercorio F, De Simone R, Di Spiezio Sardo A, et
al: The effect of a levonorgestrel-releasing
intrauterine device in the treatment of myoma-
related menorrhagia. Contraception 2003; 67:
277 – 280.
23 Wildemeersch D, Schacht E: Treatment of
intrauterine levonorgestrel-releasing drug
delivery system: a pilot study. Eur J Contracept
Reprod Health Care 2001; 6: 93 – 101.
24 Diaz J, Bahamondes L, Monteiro I, et al:
levonorgestrel-releasing intrauterine system
(Mirena®) in Campinas, Brazil. Contraception
2000; 62: 59 – 61.
25 Andersson K, Odlind V, Rybo G. Levonorgestrel-
releasing and copper-releasing (Nova-T) IUDs
during five years of use: a randomized
comparative trial. Contraception 1994; 49: 56 –
26 Kriplani A, Singh BM, Lal S, et al: Efficacy,
menorrhagia. Int J Gynaecol Obstet 2007; 97:
190 – 194.
NI, Burlev VA:
a novel ‘frameless’
performance of the
side-effects of the
Author’s address for correspondence
Associate Professor Shu Wan
The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road,
Hangzhou 310003, China.
Z-W Xie, Y-N Zhang, S Wan et al.
Levonorgestrel-releasing IUD for contraception in leiomyoma